LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.:	APPLICATION NO.:
87534-3100	09/644,456
APPLICANT:	
Vered HORNIK et al.	
FILING DATE:	**GROUP:**
August 24, 2000	1631

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
MH	AA	3,988,304	10/1976	Garsky	260	78A	
	AB	4,011,182	03/1977	Sarantakis	260	8	
	AC	4,054,558	10/1977	Garsky	260	112.5S	
	AD	4,187,217	02/1980	Chipens et al.	260	112.5R	
	AE	4,235,886	11/1980	Freidinger et al.	424	177	
	AF	4,310,518	01/1982	Freidinger et al.	424	177	
	AG	5,364,851	11/1994	Joran	530	345	
	AH	5,371,070	12/1994	Koerber et al.	514	9	
	AI	5,770,687	01/1998	Hornik et al.	530	311	
	AJ	5,874,529	02/1999	Gilon et al.	530	317	
	AK	5,883,293	06/1999	Gilon et al.	562	455	
MH	AL	6,051,554	04/2000	Hornik et al.	514	11	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	2,304,352	10/1976	France				
—	AN	2,411,828	07/1979	France				
—	AO	0 031 303	07/1981	EPO				
MH	AP	WO 89/01781	03/1989	PCT				
MH	AQ	0 334 244 A2	09/1989	EPO				
MH	AR	0 336 779 A2	10/1989	EPO				
—	AS	0 370 453 B1	05/1990	EPO				
MH	AT	0 395 417	10/1990	EPO				
MH	AU	0 336 779 A3	08/1991	EPO				
MH	AV	WO 92/00091	01/1992	PCT				
—	AW	41 19 544 C1	10/1992	Germany				
—	AX	WO 92/22566	12/1992	PCT				

		AY	WO 93/01206	01/1993	PCT				
		AZ	0 564 739 A2	10/1993	EPO				
		BA	WO 94/11393	05/1994	PCT				
		BB	WO 95/01800	01/1995	PCT				
		BC	0 564 739 A3	04/1995	EPO				

OTHER REFERENCES (*Including Author, Title, Date, Pertinent Pages, Etc.*)

		BD	Bell et al., 1993, "Molecular biology of somatostatin receptors," TINS, Vol. 16, No. 1, 34-38.
		BE	Brazeau et al, 1973, "Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreative Pituitary Growth Hormone", SCIENCE, Vol. 179, pp. 77-79
		BF	Buscail et al., 1995, "Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms," Proc. Natl. Acad. Sci. USA 92: 1580-1584.
		BG	Byk et al., 1992, "Building units for N-backbone cyclic peptides. 1. Synthesis of protected N-(ω-aminoalkylene)amino acids and their incorporation into dipeptide units", *J. Org. Chem.* 57:5687-5692
		BH	Charpentier et al., 1989, "Synthesis and binding affinities of cyclic and related linear analogues of CCK_8 selective for central receptors," J. Med. Chem., pp. 1184-1190.
		BI	Giannis et al., 1993, "Peptidomimetics for receptor ligands - discovery, development, and medical perspectives," Angew. Chem. Int. Ed. Engl. 32: 1244-1267.
		BJ	Gilon et al., 1991, "Backbone Cyclization: A New Method for Conferring Conformational Constraint on Peptides", *Biopolymers* 31:745-750
		BK	Gilon et al., 1992, "SAR studies of cycloseptide: effects of cyclization and charge at position 6," Chem. Biol. Proc. Am. Pept. Symp 1th. pp. 476-477.
		BL	Greiner et al., 1994, "Synthesis of New Backbone-Cyclized Bradykinin Analogs", *Proc. Eur. Pept. Symp.*, 23rd, Meeting Date 1994, 289-290
		BM	Hruby et al., 1990, "Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations," Biochem. J. 268: 249-262.
		BN	Klein, et al., 1995, "Interleukin-6 in Human Multiple Myeloma," Blood, Vol. 85, No. 4, pp. 863-872.
		BO	Krstenansky et al., 1994, "Cyclic hexapeptide antagonists of the bradykinin B_2 receptor: Receptor binding and solution backbone conformation", *Letters in Peptide Science* 1:229-234
		BP	Lamberts, 1988, "The role of Somastatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors," Endocrine Reviews Vol. 9, No. 4, pp. 417-436.
		BQ	Lamberts et al., 1990,"Somastatin-receptor imaging in the localization of endocrine tumors," New England J. Med. 323: 1246-1249.
		BR	Lymangrover et al., 1993, "Varying the duration of A23187 administration alters its effect on adrenal steroidogenesis," Life sciences 34:371-377.
		BS	Mosberg et al., 1983, "Bis-penicillamine enkephalins possess highly improved specificity toward δ opioid receptors," Biochemistry 80:5871-5874.
		BT	Plotsky et al., 1985, "Patterns of growth hormone-releasing factor and somatostatin secretion into the hypophysial-portal circulation of the rat," Science 230:461-463.
MM		BU	Raynor et al., 1993, "Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high

		affinity binding of linear peptides," Mol. pharmacol. 43:838-844.
	BV	Reisine et al., 1995, "Molecular biology of somatostatin receptors," Endocrine reviews 16, 427-442.
	BW	Reubi et al., 1995, "Multiple actions of somatostatin in neoplastic disease," TIPS 16: 110-115.
	BX	Rizo et al., 1992, "Constrained peptides: Models of bioactive peptides and protein substructures," Annu. Rev. Biochem. 61:387-418.
	BY	Rodriguez et al. 1990, "Synthesis of cyclic analogues of cholecystokinin highly selective for central receptors," Int. J. Peptide Protein Res. 35:441-451.
	BZ	Rudinger, 1976, "Characteristics of the Amino Acids as components of a peptide hormone sequence," Peptide Hormones, Ed. J.A. Parsons, University Park Press, Baltimore, pp.1-7
	CA	Schumann et al., 1996, Database Caplus, DN: 130:14228. Pept. 1996, Proc. Eur. Pept. Symp., 24th (1998). Meeting Date 1996, 797-798. Editors: Ramage, Robert; Epton, Roger. Publisher: Mayflower Scientific, Kingswinford, UK.
	CB	Steranka et al., 1988, "Bradykinin as a pain mediator: receptors are localized to sensory neurons, and antagonists have analgesic actions," Proc. Natl. Acad. Sci. USA 85:3245-3249.
	CC	Verber et al., 1984, "A super active cyclic hexapeptide analog of somatostatin," Life sciences 34:1371-1378.
	CD	Verber et al., 1985, "The design of metabolically-stable peptide analogs," TINS, pp. 392-396.
MM	CE	Zuckerman, 1993, "The chemical synthesis of peptidomimetic libraries," Current Opinion in Structure Biol., 3: 580-584.

EXAMINER	DATE CONSIDERED
MBrus	02/04/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANTS

(Use several sheets if necessary)

ATTY DOCKET NO	APPLICATION NO
2254-031-2 C	09 644,456
APPLICANT: HORNIK et al.	
FILING DATE: August 24 2000	GROUP: 1631

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	TRANSLATION (YES / NO)
MM	AA	5,639,455	6/1997	Shimamura et al.	424	133.1	
	AB	5,470,942	11/1995	Alexander et al.	528	328	
	AC	5,420,109	5/1995	Suto et al.	514	8	
MM	AD	5,210,075	5/1993	Scholz et al.	514	14	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
MM	AE	WO 00/72864 A1	07/2000	PCT				
	AF	WO 99/65508	12/1999	PCT				
	AG	WO 98/04583	2/1998	PCT				
	AH	WO 97/48728	12/1997	PCT				
	AI	WO 97/13781	4/1997	PCT				
	AJ	WO 97/09344	3/1997	PCT				
	AK	WO 95/33765	12/1995	PCT				
MM	AL	WO 95/13086	5/1995	PCT				

OTHER REFERENCES *(Including Author, Title, Date, Pertinent Pages, Etc.)*

MM	AM	Hirano, T., 1998, "*Interleukin 6 and its Receptor: Ten Years Later*", Intern. Rev. Immunol., 16:249.
	AN	Yoshizaki et al., 1998, "*Therapy of Rheumatoid Arthritis by Blocking IL-6 Signal Transduction with a Humanized Anti-IL-6 Receptor Antibody*", Springer Semin. Immunopathol., 20: 247.
	AO	Kozak et al., 1997, " *Sickness Behavior in Mice Deficient in Interleukin-6 During Turpentine Abscess and Influenza Pneumonitis*", American J. Physiology, 272: 2 R621.
	AP	Simpson et al., 1997, "*Interleukin-6: Structure-function Relationships*", Protein Sci., 6: 929.
	AQ	Xu et al., 1997, "*Solution Structure of Recombinant Human Interleukin-6*", J. Mol. Biol., 268: 468.
	AR	Fourcin et al., 1996, "*gp130 Transducing Receptor Cross-linking Is Sufficient to Induce Interleukin-6 Type Responses*", J. Biol. Chem., 271: 11756.
	AS	Murakamin-Mori et al., 1996, "*The Soluble Form of the IL-6 Receptor (sIL-6Rα) Is a Potent Growth Factor for AIDS-associated Kaposi's sarcoma (KS) cells; the Soluble Form of gp130 Is Antagonistic for sIL-6Rα-Induced AIDS-KS Cell Growth*", Int. Immunol., 8: 595.
MM	AT	Ogata, A., 1996, "*Therapeutic Strategies of Inhibition of Interleukin-6 Mediated Multiple Myeloma Cell Growth*". Leuk. Res., 20: 303.
	AU	*Bioactivity*", The EMBO J., 15. 2725
	AV	Halimi et al., 1995, "*Epitope Peptides from Interleukin-6 Receptor Which Inhibit the Growth of Human*
MM		

LIST OF REFERENCES CITED BY APPLICANT *(Use several sheets if necessary)*	ATTY DOCKET NO 2254-031	SERIAL NO
	APPLICANT Vered HORNIK et al.	
	FILING DATE August 24, 2000	GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
MM	AA	3,988,304	10/1976	Garsky	260	78A	
	AB	4,011,182	03/1977	Sarantakis	260	8	
	AC	4,054,558	10/1977	Garsky	260	112.5S	
	AD	4,187,217	02/1980	Chipens et al.	260	112.5R	
	AE	4,235,886	11/1980	Freidinger et al.	424	177	
	AF	4,310,518	01/1982	Freidinger et al.	424	177	
	AG	5,364,851	11/1994	Joran	530	345	
	AH	5,371,070	12/1994	Koerber et al.	514	9	
	AI	5,770,687	06/1998	Hornik et al.	530	311	
	AJ	5,874,529	02/1999	Gilon et a.	530	317	
	AK	5,883,293	06/1999	Gilon et al.	562	455	
MM	AL	6,051,554	04/2000	Hornik et al.	514	11	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
MM	AM	031 303	07/1981	European Patent Office				X
	AN	334 244	09/1989	European Patent Office				
	AO	336 779	10/1989	European Patent Office				
	AP	370 453	05/1990	European Patent Office				X
	AQ	395 417	10/1990	European Patent Office				
	AR	564 739	10/1993	European Patent Office				
	AS	2 304 352	10/1976	France				X
	AT	2 411 828	07/1979	France				X
	AU	41 19 544	10/1992	Germany				X
	AV	WO 89/01781	03/1989	WIPO				
	AW	WO 92/00091	01/1992	WIPO				
	AX	WO 92/22566	12/1992	WIPO				X
	AY	WO 93/01206	01/1993	WIPO				
	AZ	WO 94/11393	05/1994	WIPO				
MM	BA	WO 95/01800	01/1995	WIPO				

		Pituitary Growth Hormone. *Science* 179.77 79.
MM	BB	Buscail et al., 1995. "Inhibition of cell proliferation by the somatostatin analogue RC 160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms." *Proc. Natl.* 92

02/04